We are live on
!
Find out more
Primecap Management Portfolio holdings
AUM
$169B
Turnover
4.85%
1-Year Est. Return
114.72%
This Fund
S&P 500
This Quarter
Est. Return
-3.6%
1 Year Est. Return
+114.72%
3 Year Est. Return
+234.44%
5 Year Est. Return
+291.25%
10 Year Est. Return
+1,263.36%
AUM
$103B
AUM Growth
-$8.53B
(-7.6%)
Cap. Flow
-$1.35B
Cap. Flow
% of AUM
-1.3%
Top 10 Holdings %
Top 10 Hldgs %
33.19%
Holding
345
New
4
Increased
67
Reduced
190
Closed
10
Avg Time Held
5.5
years
Top 10 Avg Time Held
5
years
Top 20 Avg Time Held
5.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BeOne Medicines Ltd
ONC
|
+$121M |
| 2 |
Intel
INTC
|
+$120M |
| 3 |
JB Hunt Transport Services
JBHT
|
+$112M |
| 4 |
FedEx
FDX
|
+$93.9M |
| 5 |
Royal Caribbean
RCL
|
+$63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Charles Schwab
SCHW
|
+$418M |
| 2 |
Morgan Stanley
MS
|
+$236M |
| 3 |
POLY
Plantronics, Inc.
POLY
|
+$214M |
| 4 |
Marsh
MRSH
|
+$210M |
| 5 |
Eli Lilly
LLY
|
+$133M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.79% |
| 2 | Technology | 26.81% |
| 3 | Industrials | 11.2% |
| 4 | Consumer Discretionary | 9.81% |
| 5 | Financials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$1.12T
| $9.06B | 8.77% |
28,017,155
-421,333
| -1% | -$133M |
2013 Q2
37 quarters
|
|
2
Biogen
BIIB
$34.8B
| $4.2B | 4.07% |
15,741,715
+15,189
| +0.1% | +$3.23M |
2013 Q2
37 quarters
|
|
3
Amgen
AMGN
$235B
| $3.51B | 3.39% |
15,564,870
-73,750
| -0.5% | -$17.9M |
2013 Q2
37 quarters
|
|
4
Microsoft
MSFT
$4.01T
| $3.38B | 3.27% |
14,516,240
-377,480
| -3% | -$99.7M |
2013 Q2
37 quarters
|
|
5
Tesla
TSLA
$1.43T
| $2.69B | 2.6% |
10,125,710
-90,550
| -0.9% | -$25.3M |
2013 Q2
37 quarters
|
|
6
Texas Instruments
TXN
$255B
| $2.68B | 2.6% |
17,346,527
-171,240
| -1% | -$28.7M |
2013 Q2
37 quarters
|
|
7
AstraZeneca
AZN
$259B
| $2.5B | 2.42% |
22,807,055
-99,855
| -0.4% | -$12.7M |
2015 Q3
28 quarters
|
|
8
KLA
KLAC
$228B
| $2.15B | 2.08% |
71,107,940
-705,600
| -1% | -$24.4M |
2013 Q2
37 quarters
|
|
9
Alphabet (Google) Class A
GOOGL
$4.27T
| $2.06B | 2% |
21,584,240
-150,640
| -0.7% | -$16.7M |
2015 Q3
28 quarters
|
|
|
10
FedEx
FDX
$69.9B
| $2.06B | 1.99% |
13,878,717
+445,125
| +3% | +$93.9M |
2013 Q2
37 quarters
|
|
11
Micron Technology
MU
$1.05T
| $2.03B | 1.96% |
40,434,127
+13,911
| +0% | +$807K |
2013 Q2
37 quarters
|
|
12
Wells Fargo
WFC
$248B
| $1.95B | 1.89% |
48,582,875
-245,450
| -0.5% | -$10.5M |
2013 Q2
37 quarters
|
|
13
Thermo Fisher Scientific
TMO
$258B
| $1.93B | 1.86% |
3,797,057
-55,395
| -1% | -$31M |
2013 Q4
35 quarters
|
|
14
Adobe
ADBE
$97.9B
| $1.76B | 1.71% |
6,404,918
-66,900
| -1% | -$25.3M |
2013 Q2
37 quarters
|
|
15
Southwest Airlines
LUV
$20B
| $1.63B | 1.57% |
52,741,484
-178,440
| -0.3% | -$6.68M |
2013 Q2
37 quarters
|
|
16
Sony
SONY
$144B
| $1.62B | 1.56% |
126,239,340
-416,150
| -0.3% | -$6.67M |
2013 Q2
37 quarters
|
|
17
Bristol-Myers Squibb
BMY
$124B
| $1.57B | 1.52% |
22,137,675
-74,030
| -0.3% | -$5.37M |
2017 Q1
22 quarters
|
|
18
BioMarin Pharmaceuticals
BMRN
$10.8B
| $1.49B | 1.45% |
17,625,505
-52,980
| -0.3% | -$4.72M |
2013 Q2
37 quarters
|
|
19
Boston Scientific
BSX
$64B
| $1.46B | 1.41% |
37,650,309
-169,300
| -0.4% | -$6.79M |
2013 Q2
37 quarters
|
|
20
Alphabet (Google) Class C
GOOG
$4.22T
| $1.4B | 1.35% |
14,514,240
-131,600
| -0.9% | -$14.7M |
2013 Q2
37 quarters
|
|
21
Alibaba
BABA
$276B
| $1.39B | 1.35% |
17,386,207
+18,320
| +0.1% | +$1.75M |
2014 Q3
32 quarters
|
|
|
22
Intel
INTC
$504B
| $1.34B | 1.3% |
52,117,226
+3,518,980
| +7% | +$120M |
2013 Q2
37 quarters
|
|
23
Raymond James Financial
RJF
$30.3B
| $1.34B | 1.29% |
13,539,327
-50,290
| -0.4% | -$5.09M |
2018 Q4
15 quarters
|
|
24
Novartis
NVS
$286B
| $1.33B | 1.28% |
17,453,150
-150,930
| -0.9% | -$12.5M |
2013 Q2
37 quarters
|
|
25
Aecom
ACM
$7.6B
| $1.31B | 1.27% |
19,189,841
-209,075
| -1% | -$14.8M |
2013 Q2
37 quarters
|
|
Similar funds
Primecap Management's Q3 2022 Portfolio in Review
As of Q3 2022, Primecap Management held 345 positions worth $103B, down 7.6% from $112B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Trading was light in Q3 2022: portfolio turnover was 4.1%. Primecap Management opened 4 new positions and exited 10, leaving the 345-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 31% a quarter earlier, followed by Technology and Industrials.
- Primecap Management's largest Q3 2022 buy was JB Hunt Transport Services: 642,100 shares worth $100M.
- Primecap Management added most to BeOne Medicines Ltd in Q3 2022, an estimated $121M increase.
- Primecap Management's biggest Q3 2022 reduction was Charles Schwab, cutting an estimated $418M.
- Primecap Management fully exited Plantronics, Inc. in Q3 2022, selling an estimated $214M.
- Primecap Management's ten largest holdings make up 33% of its $103B portfolio in Q3 2022.
- Primecap Management opened 4 new positions and closed 10 in Q3 2022.
- Primecap Management's portfolio value fell 7.6% quarter-over-quarter to $103B.
Based on Primecap Management's 13F filing for Q3 2022, filed 14 Nov 2022.